Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering

The aim of the partnership is to provide a platform delivering high-end performance with an optimal cost-of-goods and price-per-dose model to ease scale-up, commercial strategy, and fundraising efforts for drug developers.

The post Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering appeared first on GEN - Genetic Engineering and Biotechnology News.